18.32  -0.96 (-4.98%)		08-26 15:15
Open: 18.96 High: 19.08 Volume: 983,647		Pre. Close: 19.28 Low: 18.27 Market Cap: 1,326(M)

Short term
Mid term
Targets	6-month :	22.95	1-year :	26.8
Resists	First :	19.64	Second :	22.95
Pivot price	16.64
Supports	First :	13.43	Second :	9.6
MAs	MA(5) :	18.98	MA(20) :	15.58
	MA(100) :	12.29	MA(250) :	10.47
MACD	MACD :	2.1	Signal :	1.8
%K %D	K(14,3) :	91.6	D(3) :	94.5
RSI	RSI(14): 75
52-week	High :	19.64	Low :	3.94

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ OMER ] has closed below upper band by 31.1%. Bollinger Bands are 151.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	19.67 - 19.76	19.76 - 19.83
Low:	18.88 - 19.01	19.01 - 19.1
Close:	19.09 - 19.29	19.29 - 19.42

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Tue, 25 Aug 2026
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

Tue, 25 Aug 2026
OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations - Stocktwits

Tue, 25 Aug 2026
Why Omeros (OMER) Is Up 11.3% After Swinging To Profit And Stepping Up Capital Moves - simplywall.st

Sat, 22 Aug 2026
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now - Eastern Progress

Fri, 21 Aug 2026
Omeros Corp (OMER) Director Thomas Cable Sells 15,000 Shares - GuruFocus

Wed, 12 Aug 2026
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates - Eastern Progress

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	72 (M)
Shares Float	69 (M)
Held by Insiders	4 (%)
Held by Institutions	50.4 (%)
Shares Short	15,420 (K)
Shares Short P.Month	15,140 (K)

EPS	1.64
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.71
Profit Margin	324.8 %
Operating Margin	0.2 %
Return on Assets (ttm)	-18.7 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.2
Sales Per Share	0.53
EBITDA (p.s.)	-1
Qtrly Earnings Growth	0 %
Operating Cash Flow	-69 (M)
Levered Free Cash Flow	183 (M)

PE Ratio	11.17
PEG Ratio	0.8
Price to Book value	-25.97
Price to Sales	34.74
Price to Cash Flow	-19.44

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.